2021
Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma.
Patel KK, Giri S, Parker TL, Bar N, Neparidze N, Huntington SF. Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma. Journal Of Clinical Oncology 2021, 39: 1119-1128. PMID: 33411586, DOI: 10.1200/jco.20.01849.Peer-Reviewed Original ResearchConceptsTransplant-ineligible patientsIncremental cost-effectiveness ratioFirst-line settingHealthcare costsClinical outcomesMultiple myelomaProgression-free survivalOverall survival dataUS payer perspectiveDirect healthcare costsCost-effectiveness ratioRandomized trialsDisease progressionTreatment strategiesParametric survival modelingPayer perspectiveSubsequent linesLater linesPatientsCostly treatmentIncremental costQALYSurvival dataLenalidomideMyeloma
2014
Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments.
Neparidze N, Lacy J. Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments. Clinical Advances In Hematology And Oncology 2014, 12: 358-71. PMID: 25003566.Peer-Reviewed Original ResearchConceptsEpstein-Barr virusClinical featuresEBV-specific T-cell therapyInhibition of EBVTreatment of EBVT-cell lymphomaT-cell therapyNew treatment strategiesEBV vaccineImmune dysregulationHodgkin's lymphomaNasopharyngeal cancerTreatment strategiesGastric cancerTherapeutic approachesBurkitt's lymphomaEBV oncogenesisAntiviral drugsLymphoid neoplasmsViral infectionLymphomaImmunogenic propertiesLytic viral infectionPathobiologyMalignancy